Program
platelet rich plasma
Also written as “Platelet-Rich Plasma (PRP) Injections”, “[PRP] platelet rich plasma” and “Autologous PRP Gel and PRP Injection”.
Its studies are mostly in Osteoarthritis · Alopecia · Osteoarthritis, Knee · Diphtheria · Pain, led by 8 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bioheart | 10 open or running | phase 1since Mar 15, 2017 | Mar 15, 2017 | none ahead |
| Exactech | 10 open or running | phase 4since Jan 20, 2009 | Jan 20, 2009 | none ahead |
| Integrant Pty | 11 open or running | phase 3since Mar 26, 2025 | Mar 26, 2025 | Aug 2027phase 3 · NCT06907121 |
| Kimberly Meathrel | 11 open or running | early phase 1since Jul 28, 2026 | Jul 28, 2026 | Dec 30, 2027early phase 1 · NCT07739147 |
| PT. Prodia Stem Cell Indonesia | 11 open or running | phase 2since Feb 17, 2026 | Feb 17, 2026 | none ahead |
| QC Kinetix | 10 open or running | phase 2since Feb 6, 2023 | Feb 6, 2023 | none ahead |
| TotipotentRX Cell Therapy Pvt. | 10 open or running | phase 1since Jan 4, 2017 | Jan 4, 2017 | none ahead |
| Zimmer Biomet | 10 open or running | no phasesince Sep 22, 2008 | Sep 22, 2008 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 22, 2008First study: no phase study in PainNew to Zimmer BiometZimmer Biomet · NCT00757289 · 106 enrolled · Netherlands
- Jan 20, 2009Exactech's first study: phase 4 study in OsteoarthritisNew to ExactechExactech · NCT00826098 · 70 enrolled · United States
- Jan 4, 2017TotipotentRX Cell Therapy Pvt.'s first study: phase 1 study in Chronic UlcerNew to TotipotentRX Cell Therapy Pvt.TotipotentRX Cell Therapy Pvt. · NCT03026855 · 24 enrolled · India
- Mar 15, 2017Bioheart's first study: phase 1 study in OsteoarthritisNew to BioheartBioheart · NCT03089762 · 10 enrolled
- Feb 6, 2023QC Kinetix's first study: phase 2 study in Osteoarthritis, KneeNew to QC KinetixQC Kinetix · NCT05742763 · United States
- Mar 26, 2025Integrant Pty's first study: phase 3 study in Arthritis AnkleNew to Integrant PtyIntegrant Pty · NCT06907121 · 192 planned · Australia
- Feb 17, 2026PT. Prodia Stem Cell Indonesia's first study: phase 2 study in AlopeciaNew to PT. Prodia Stem Cell IndonesiaPT. Prodia Stem Cell Indonesia · NCT07429253 · 40 planned · Indonesia
- Jul 28, 2026Kimberly Meathrel's first study: early phase 1 study in AlopeciaNew to Kimberly MeathrelKimberly Meathrel · NCT07739147 · 30 planned
Ahead
- Aug 2027Primary completion: phase 3 study in Arthritis AnkleIntegrant Pty · NCT06907121
- Dec 30, 2027Primary completion: early phase 1 study in AlopeciaKimberly Meathrel · NCT07739147
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07739147Alopecia | Early 1 | Not yet recruiting | Kimberly Meathrel | Dec 30, 2027 | 30 |
| NCT07429253Alopecia · Indonesia | 2 | Recruiting | PT. Prodia Stem Cell Indonesia | Jun 30, 2026 | 40 |
| NCT06907121Arthritis Ankle · Australia | 3 | Not yet recruiting | Integrant Pty | Aug 2027 | 192 |
| NCT05742763Osteoarthritis, Knee · United States | 2 | Withdrawn | QC Kinetix | Oct 7, 2024 | 0 |
| NCT03089762Osteoarthritis | 1 | Completed | Bioheart | Dec 30, 2014 | 10 |
| NCT03026855Chronic Ulcer · India | 1 | Completed | TotipotentRX Cell Therapy Pvt. | Apr 2016 | 24 |
| NCT00826098Osteoarthritis · United States | 4 | Completed | Exactech | Jun 2011 | 70 |
| NCT00757289Pain · Netherlands | – | Completed | Zimmer Biomet | Jan 2008 | 106 |
How it is read
Names in the registry
- “Platelet-Rich Plasma (PRP) Injections”, 2 entries
- “[PRP] platelet rich plasma”, 2 entries
- “Autologous PRP Gel and PRP Injection”, 2 entries
- “Intra-Articular Injection of Growth Hormone and Platelet-Rich Plasma”, 1 entry
- “Ibuprofen and PRP”, 1 entry
Conditions, from the studies’ own filings
- Osteoarthritis, 3 studies
- Alopecia, 2 studies
- Osteoarthritis, Knee, 1 study
- Diphtheria, 1 study
- Pain, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.